STOCK TITAN

Sight Sciences, Inc. SEC Filings

SGHT NASDAQ

Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Regulatory filings from an ophthalmic device maker can feel as technical as a surgical manual. Sight Sciences’ 10-K alone dives into FDA clearance pathways, real-world data for the OMNI Surgical System, and reimbursement hurdles for TearCare. Missing one paragraph could mean overlooking a projected shift in surgeon adoption or a new clinical-trial milestone.

Stock Titan answers that problem instantly. Our AI parses every Sight Sciences SEC filing the moment it posts to EDGAR—whether it is a Sight Sciences quarterly earnings report 10-Q filing or an unexpected Sight Sciences 8-K material events explained. You’ll get plain-English summaries, key financial tables, and red-flag alerts on regulatory updates, so you can focus on decisions, not page counts.

Need real-time trading intelligence? Follow Sight Sciences insider trading Form 4 transactions in minutes, complete with contextual commentary on executive behavior. Digging into growth drivers? Our platform links OMNI unit sales and TearCare placement figures straight from the Sight Sciences annual report 10-K simplified. Curious about leadership pay? The Sight Sciences proxy statement executive compensation is decoded so you can compare incentive structures to clinical performance.

  • AI-powered highlights for every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A
  • Form 4 insider alerts: Sight Sciences Form 4 insider transactions real-time
  • Side-by-side earnings trend charts and Sight Sciences earnings report filing analysis

Understanding Sight Sciences SEC documents with AI means knowing exactly when clinical data, reimbursement shifts, or executive stock transactions Form 4 could reshape the outlook for this innovative MIGS and dry-eye pioneer—no medical jargon required.

Filing
Rhea-AI Summary

Form 144 filed for Sight Sciences, Inc. (SGHT) discloses a contemplated insider disposition of 5,679 common shares through Fidelity Brokerage Services on 07 / 03 / 2025. At the most recent market price, the block is valued at $23,705.28. With 51,702,088 shares outstanding, the proposed sale equates to just 0.011 % of the float, suggesting minimal market impact.

The seller acquired the shares via restricted-stock vesting on 06 / 30 / 2025 as compensation. No other sales were reported in the past three months, and the filer attests to possessing no undisclosed adverse information. Under Rule 144, the notice creates a 90-day window in which the shares may be sold; actual execution will be confirmed, if it occurs, by a subsequent Form 4.

Although the dollar amount is immaterial in relation to SGHT’s capitalization, investors often view any insider sale as a potential sentiment signal. Monitoring future filings will clarify whether this event reflects routine liquidity or the start of a broader selling pattern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Summary

Sight Sciences, Inc. (SGHT) filed a Form 144, providing notice of a proposed sale of restricted securities by an affiliate. The filing covers the planned disposition of 9,160 common shares, valued at approximately $38,235.67 based on prevailing market prices. The shares, which vested as restricted-stock compensation on 06/30/2025, are slated to be sold through Fidelity Brokerage Services on or about 07/03/2025 on NASDAQ.

With 51.7 million shares outstanding, the contemplated sale represents less than 0.02 % of total shares and therefore is unlikely to have a material impact on the float or trading dynamics. The filer reported no other insider sales in the past three months. While Form 144 sales signal insider liquidity activity, the modest size and compensation-related origin suggest routine portfolio management rather than a directional view on the company’s fundamentals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Summary

Stratus Properties Inc. (STRS) – Form 4 filing: Director Laurie L. Dotter acquired 321 shares of STRS common stock on 07/01/2025 at an average price of $18.88 per share. The shares were issued pursuant to her prior election to receive a portion of her annual board retainer in equity rather than cash, rather than an open-market purchase. Following the transaction, Dotter’s total beneficial ownership increased to 18,273 shares, which includes 3,730 restricted stock units (RSUs). The filing shows the transaction was executed directly and no derivative securities were involved.

The disclosed purchase is modest in absolute terms and represents routine director compensation, but it modestly aligns the director’s economic interests with shareholders by converting cash fees into equity. There is no indication of simultaneous sales or other insider transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Filing
Rhea-AI Summary

Enstar Group Limited (NASDAQ: ESGR) has formally completed its previously announced take-private transaction. On 2 July 2025 the insurer executed a three-step merger structure with entities backed by Sixth Street Partners, LLC, resulting in Enstar becoming a wholly-owned subsidiary of Elk Bidco Limited (the “Parent”). The aggregate consideration is approximately $5.1 billion.

Cash consideration to ordinary shareholders: each Enstar ordinary share has been converted into the right to receive $338 in total cash (delivered through payments at the first and third merger steps). A portion of the $338 was first paid out of a fixed $500 million pool, with the balance settled at the third merger step, as detailed in the Merger Agreement.

Preferred shares: Series C, D and E preferred shares were automatically converted, step-for-step, into equivalent preferred shares of the surviving private entity, maintaining all existing dividend rates and other preferences.

Equity awards: • Service-based restricted shares vested immediately and were cashed out at $338 per share. • RSUs rolled into units of the new holding company, then the surviving private entity, and were fully vested and cashed out at closing. • A prorated portion of PSU awards vested based on actual performance and was paid in cash; the remainder was forfeited.

Listing status & reporting obligations: Trading in Enstar ordinary shares and the Series D and E depositary shares has been suspended. The company has instructed Nasdaq to file Form 25s on or about 14 July 2025 to delist and deregister the securities. A Form 15 will follow, terminating registration under Section 12(g) and suspending Exchange Act reporting duties.

Governance changes: The entire legacy board resigned at the third merger step. A new 13-member board, dominated by appointees of Sixth Street, has been installed. Enstar’s bye-laws have been replaced by those of the merger subsidiary (with only the name amended).

Financing for the transaction came from Enstar resources, equity from Sixth Street managed funds, and third-party equity and debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Summary

Viking Holdings Ltd (VIK) – Form 144 overview: The filing discloses that insider Jeffrey Dash has notified the SEC of his intent to sell up to 25,000 ordinary shares of Viking Holdings through broker Morgan Stanley Smith Barney LLC. The proposed sale, scheduled for 01 July 2025, carries an aggregate market value of $1.33 million, based on prevailing market prices. Viking currently has 314,950,576 shares outstanding; the new sale therefore represents roughly 0.008 % of total shares.

Recent 10b5-1 activity: The same account has conducted four 10b5-1 sales in the last three weeks, totaling 150,000 shares for gross proceeds of $7.33 million (06/12/2025–06/26/2025). Including the newly noticed shares, cumulative planned and completed sales over the period reach 175,000 shares, or about 0.055 % of shares outstanding.

Key contextual points for investors:

  • The filing is solely a notice of intention; the sale may or may not occur, but the insider must file if the sale could exceed Rule 144 thresholds.
  • Sales are being made under a pre-arranged Rule 10b5-1 plan, which can mitigate concerns of trading on undisclosed information.
  • The dollar amounts are modest relative to Viking’s equity base, yet a pattern of insider liquidation—even in small increments—can influence sentiment, particularly for newly public or thinly traded stocks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Sight Sciences (SGHT)?

The current stock price of Sight Sciences (SGHT) is $4.21 as of July 3, 2025.

What is the market cap of Sight Sciences (SGHT)?

The market cap of Sight Sciences (SGHT) is approximately 219.7M.

What is the core focus of Sight Sciences, Inc.?

Sight Sciences, Inc. is focused on developing innovative ophthalmic devices for treating glaucoma and dry eye disease. Its core technologies address key clinical challenges with advanced surgical and non-surgical procedures.

How does Sight Sciences generate its revenue?

The company generates revenue primarily through the direct sale of its specialized medical devices to eye care professionals and healthcare facilities. This includes both surgical instruments and dry eye treatment devices.

Which segments does the company operate in?

Sight Sciences operates in two main segments: the Surgical Glaucoma segment, which focuses on minimally invasive procedures to manage intraocular pressure, and the Dry Eye segment, which offers solutions for non-surgical management of dry eye disease.

How does the technology help in treating glaucoma?

The surgical technology combines canaloplasty and trabeculotomy through a single device and corneal incision. This dual-action approach effectively reduces intraocular pressure and decreases the reliance on medications.

What differentiates Sight Sciences from its competitors?

The company distinguishes itself by integrating clinical research with device innovation. Its products offer dual functionalities, supported by clinical studies and real-world data, which contribute to more efficient procedural outcomes.

Who typically uses the devices developed by Sight Sciences?

The devices are primarily used by ophthalmologists, optometrists, and healthcare facilities specializing in eye care. They are designed to enhance procedural efficacy and improve patient outcomes in clinical settings.

How does clinical research support the company's products?

Robust clinical trials and real-world studies validate the efficacy of Sight Sciences' devices. These studies provide evidence on improved patient outcomes, such as reduced intraocular pressure and enhanced management of dry eye symptoms, thereby reinforcing the company’s clinical credibility.
Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Stock Data

219.73M
40.72M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK